# US 2008/0306148 A1 · Anti-cancer compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306148 A1
- Document ID: US20080306148A1
- Status: Published application
- Kind: A1
- Application number: 12/102,629
- Filed: 2008-04-14
- Published: 2008-12-11
- Earliest claimed: 2007-04-13
- Assignees: The Penn State Research Foundation
- Inventors: Gavin P. Robertson; Arati K. Sharma; Arun K. Sharma; Shantu Amin; Dhimant Desai
- Web page: https://patentgrep.com/patent/US20080306148A1

## CPC

- C07C 391/00: Compounds containing selenium
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/095: Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K 31/21: Esters, e.g. nitroglycerine, selenocyanates
- A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07C 251/00: Compounds containing nitrogen atoms doubly-bound to a carbon skeleton (diazo compounds C07C245/12)
- C07C 331/24: the carbon skeleton containing six-membered aromatic rings
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Anti-cancer compositions and methods are described including one or more isothiocyanates and/or isoselenocyanates. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation.

## Claims

### Claim 1

A composition comprising an isoselenocyanate having the structural formula:
R—(CH2)n—N═C═Se, where n is an integer in the range of 1-8, inclusive, and where R is selected from the group consisting of: an aromatic group and a non-aromatic organic group.

### Claim 2 (depends on 1)

The composition of claim 1 where the isoselenocyanate has the structural formula:
where R′ is a substituted or unsubstituted, branched or straight chain, lower alkyl group, and where n is an integer in the range of 3-8, inclusive.

### Claim 3 (depends on 2)

The composition of claim 2 wherein R′ is CH3.

### Claim 4 (depends on 2)

The composition of claim 2, where R′ is CH3 and n is 4.

### Claim 5

A method for synthesis of an isoselenocyanate having the structural formula: R—(CH2)n—N═C═Se, where n is an integer in the range of 1-8, inclusive, and where R is selected from the group consisting of: an unsubstituted aromatic group; an aromatic group substituted by one or more substituents selected from the group consisting of: F, Cl, Br, a lower alkyl group, a lower alkoxy group and a fluorinated lower alkyl group; R′—S(O), where R′ is a lower alkyl group, which may be substituted or unsubstituted, branched or straight chain; and CH2═CH, comprising:
formylation of a starting alkylamine compound having the structural formula: R—(CH2)n—NH2, where n is an integer in the range of 1-8, inclusive, where R is selected from the group consisting of: an unsubstituted aromatic group; an aromatic group substituted by one or more substituents selected from the group consisting of: F, Cl, Br, a lower alkyl group, a lower alkoxy group and a fluorinated lower alkyl group; R′—S(O), where R′ is a lower alkyl group, which may be substituted or unsubstituted, branched or straight chain, to produce a formylated intermediate having the structural formula: R—(CH2)n—NHCHO, where n and R are identical to R and n of the starting alkylamine;
contacting the formylated intermediate with triphosgene and selenium powder in the presence of triethylannine.

### Claim 6 (depends on 5)

The method of claim 5, wherein the formylated intermediate is contacted with triphosgene and selenium powder in the presence of triethylanine and in the presence of a solvent.

### Claim 7

A pharmaceutical composition, comprising:
a compound having the structural formula:
R—(CH2)n—N═C═X, where n is an integer in the range of 1-8, inclusive, where X is S or Se, and where R is selected from the group consisting of: an aromatic group and a non-aromatic organic group.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the compound is selected from the group consisting of: a phenylalkyl isothiocyanate, a phenylalkyl isoselenocyanate, and a combination thereof.

### Claim 9 (depends on 7)

The pharmaceutical composition of claim 7, wherein the compound is an isoselenocyanate having the structural formula selected from the group consisting of:
where n is 4 or 6;
and
where R′ is a substituted or unsubstituted, branched or straight chain, lower alkyl group, and where n is an integer in the range of 1-8, inclusive; and
a pharmaceutically acceptable carrier.

### Claim 10 (depends on 7)

The composition of claim 7, further comprising a pharmaceutically acceptable carrier.

### Claim 11 (depends on 7)

The composition of claim 7, wherein the pharmaceutical composition is formulated for topical application.

### Claim 12

A method of treating a subject, comprising:
administering a therapeutically effective amount of a composition comprising a compound having the structural formula:
R—(CH2)n—N═C═X, where n is an integer in the range of 1-8, inclusive, where X is S or Se, and where R is selected from the group consisting of: an aromatic group and a non-aromatic organic group to a subject in need thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the composition comprises a compound having the structural formula:
phenyl-(CH2)n—N═C═X, where n is an integer in the range of 1-8, inclusive, where X is S or Se.

### Claim 14 (depends on 12)

The method of claim 12, wherein the composition comprises an isoselenocyanate having the structural formula:
where R′ is a substituted or unsubstituted, branched or straight chain, lower alkyl group, and where n is an integer in the range of 3-8, inclusive.

### Claim 15 (depends on 14)

The method of claim 14 wherein R′ is CH3.

### Claim 16 (depends on 12)

The method of claim 12, wherein the composition comprises a phenylalkyl isoselenocyanate having the structural formula:
where n is 4 or 6.

### Claim 17 (depends on 12)

The method of claim 12 wherein the isoselenocyanate is selected from the group consisting of: an isoselenocyanate glutathione conjugate; an isoselenocyanate cysteine conjugate; and an isoselenocyanate N-acetylcysteine conjugate.

### Claim 18 (depends on 12)

The method of claim 12 wherein the subject is human.

### Claim 19 (depends on 12)

The method of claim 12 wherein the subject has or is at risk of having cancer.

### Claim 20 (depends on 19)

The method of claim 19 wherein the cancer is a melanoma.

### Claim 21 (depends on 12)

The method of claim 12 wherein the composition is formulated for topical application.

### Claim 22 (depends on 19)

The method of claim 19 wherein the cancer is characterized by dysregulation of Akt.

### Claim 23 (depends on 19)

The method of claim 19 wherein the cancer is characterized by dysregulation of Akt3.

### Claim 24 (depends on 19)

The method of claim 19, wherein administering the therapeutically effective amount of the composition to a subject detectably increases apoptosis and/or decreases proliferation of cells of the cancer.

### Claim 25 (depends on 19)

The method of claim 19, further comprising administration of an adjunct anti-cancer treatment.

### Claim 26

A method of modulating Akt dysregulation in a cell, comprising:
contacting the cell with an effective amount of an isoselenocyanate having the structural formula: R—(CH2)n—N═C═Se, where n is an integer in the range of 1-8, inclusive, and where R is selected from the group consisting of: an aromatic group and a non-aromatic organic group.

### Claim 27 (depends on 26)

The method of claim 26 wherein contacting the cell decreases a component of an Akt signaling pathway selected from the group consisting of: an Akt1 signaling pathway; an Akt2 signaling pathway; an Akt3 signaling pathway; and a combination thereof.
